Wells Fargo dispatches biotech banker to Cambridge/Boston supercluster

With the Cambridge/Boston biotech supercluster forming a kind of global crossroads for drug development, bankers are going the extra mile to get in on the act. In Wells Fargo's case, it's going an extra 3,000 miles out of its way. Wells Fargo life sciences specialist Katherine Andersen is uprooting herself from Palo Alto, CA, to make the trek to Boston. "It's challenging to grow relationships from 3,000 miles away," Andersen told the Boston Globe. Story

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.